Clinical trial
Topotecan Pharmacokinetic Characterization Study
NCT00361803 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00361803 |
|---|---|
| Title | Topotecan Pharmacokinetic Characterization Study |
| Official title | A Phase I Study to Characterize the Pharmacokinetics of 4 mg/m2 Weekly Intravenous Topotecan in Patients With Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | topotecan |
| Enrollment | 15 |
| Start date | Sep 12, 2006 |
| Primary completion | Aug 9, 2007 |
| Completion | Aug 9, 2007 |
| First posted | Aug 9, 2006 |
| Last update posted | Nov 17, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: